Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study
SCHUSTER, Herbert, BARTER, Philip J, STENDER, Steen, CHEUNG, Raphael C, BONNET, Jacques, MORRELL, Jonathan M, WATKINS, Claire, KALLEND, David, RAZA, Ali
Published in The American heart journal (01.04.2004)
Published in The American heart journal (01.04.2004)
Get full text
Journal Article
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia
Chong, Taryne, Naples, Mark, Federico, Lisa, Taylor, Denise, Smith, Graham J., Cheung, Raphael C., Adeli, Khosrow
Published in Atherosclerosis (01.03.2006)
Published in Atherosclerosis (01.03.2006)
Get full text
Journal Article
Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes
Gratl, Victoria, Cheung, Raphael C., Chen, Biao, Taghibiglou, Changiz, Van Iderstine, Stephen C., Adeli, Khosrow
Published in Atherosclerosis (01.07.2002)
Published in Atherosclerosis (01.07.2002)
Get full text
Journal Article
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes
Pontrelli, Louisa, Parris, Wendy, Adeli, Khosrow, Cheung, Raphael C.
Published in Metabolism, clinical and experimental (01.03.2002)
Published in Metabolism, clinical and experimental (01.03.2002)
Get full text
Journal Article
Treatment with atorvastatin ameliorates hepatic very[ndash ]low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: Evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity
Mangaloglu, Leyla, Cheung, Raphael C., Van Iderstine, Stephen C., Taghibiglou, Changiz, Pontrelli, Louisa, Adeli, Khosrow
Published in Metabolism, clinical and experimental (01.04.2002)
Published in Metabolism, clinical and experimental (01.04.2002)
Get full text
Journal Article
Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study11Herbert Schuster is the principal investigator of the MERCURY I trial, which is sponsored by AstraZeneca; he also serves on the International Rosuvastatin Advisory Board. Philip J. Barter is an investigator of the MERCURY I trial and also serves on the International Rosuvastatin Advisory Board. Steen Stender, Raphael C. Cheung, Jacques Bonnet, an
Schuster, Herbert, Barter, Philip J, Stender, Steen, Cheung, Raphael C, Bonnet, Jacques, Morrell, Jonathan M, Watkins, Claire, Kallend, David, Raza, Ali
Published in The American heart journal (01.04.2004)
Published in The American heart journal (01.04.2004)
Get full text
Journal Article
Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study 1 1 Herbert Schuster is the principal investigator of the MERCURY I trial, which is sponsored by AstraZeneca; he also serves on the International Rosuvastatin Advisory Board. Philip J. Barter is an investigator of the MERCURY I trial and also serves on the International Rosuvastatin Advisory Board. Steen Stender, Raphael C. Cheung, Jacques Bonnet,
Schuster, Herbert, Barter, Philip J, Stender, Steen, Cheung, Raphael C, Bonnet, Jacques, Morrell, Jonathan M, Watkins, Claire, Kallend, David, Raza, Ali
Published in The American heart journal (2004)
Published in The American heart journal (2004)
Get full text
Journal Article